The RLIG1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell pool developed for loss?of?function analysis of the RLIG1 gene in the human hepatic adenocarcinoma cell line SK-HEP-1. This product is produced by transient delivery of a Cas9/sgRNA ribonucleoprotein complex targeting RLIG1, resulting in a mixed population of edited alleles that disrupt gene expression. The polyclonal format preserves genetic heterogeneity, minimizing clonal selection biases and providing a reliable platform for studying mitochondrial RNA processing. These cells empower investigations into RLIG1 function within the context of hepatocellular carcinoma.
The SK-HEP-1 cell line, derived from a male liver adenocarcinoma patient, is a widely used model for hepatocellular carcinoma research. It exhibits epithelial characteristics and is particularly valuable for exploring metabolic reprogramming and drug resistance. SK-HEP-1 cells are amenable to CRISPR/Cas9 editing due to their high transfection efficiency and rapid growth, making them an ideal host for generating RLIG1 knockouts. This cell line provides a relevant hepatic tumor background for dissecting mitochondrial RNA biology.
RLIG1 encodes a mitochondrial RNA ligase essential for sealing nicked RNA species with 5??-OH and 2??,3??-cyclic phosphate ends, a process critical for mitochondrial tRNA maturation and mt?mRNA repair. Its activity is regulated upstream by the transcription factors NRF1 and PPARGC1A (PGC?1??), which respond to mitochondrial stress signals. Downstream, RLIG1 acts on mitochondrial tRNAs and nicked mt?mRNAs and interacts with mitochondrial RNA?binding proteins and potential archease cofactors. The enzyme operates within a network including PNPT1, ELAC2, MTPAP, and SUPV3L1, and its disruption likely impairs oxidative phosphorylation.
In the SK-HEP-1 hepatocellular carcinoma context, RLIG1 knockout provides a model to study how mitochondrial RNA processing defects influence tumor cell metabolism and survival. Liver cancer cells often rely on mitochondrial adaptations; loss of RLIG1 may exacerbate RNA processing errors, destabilizing oxidative phosphorylation and triggering stress responses. This system helps elucidate whether mitochondrial RNA repair pathways represent vulnerabilities in hepatic tumors and can be leveraged for therapeutic target validation. Additionally, it may uncover synthetic lethal interactions specific to HCC.
Applications for these RLIG1 knockout polyclonal SK-HEP-1 cells include RT?qPCR monitoring of mitochondrial RNA transcript levels, western blotting for mitochondrial proteins, Seahorse metabolic flux analysis, mitochondrial DNA content measurement, and apoptosis assays. RNA immunoprecipitation can probe RLIG1 interactors and targets. The polyclonal knockout pool supports high?throughput screening, making it suitable for drug discovery in mitochondrial dysfunction and liver cancer. For further inquiries, please contact Ascent Research.
